Stories
Bernstein Slashes PB Fintech Price Target by 53%, Calls Next 18 Months 'Do-or-Die'
- •Bernstein drastically cut its price target for PB Fintech to ’1,085 from ’2,310, a 53% reduction, despite maintaining an "outperform" rating.
- •The revision reflects harsher-than-expected commission cut proposals from the IRDAI, impacting general insurance take rates.
- •Bernstein suggests PB Fintech may need to scale back general insurance or find alternative revenue models to offset lost income in the health segment.
- •The brokerage expects the point of sales person (POSP) business to scale down, but sees long-term growth potential beyond FY28.
- •The next 18 months are deemed "do-or-die" for PB Fintech, with a wide range of outcomes possible amid regulatory changes and market pressures.
Key Questions Answered
Bernstein lowered its price target to ₹1,085 per share to reflect harsher-than-expected commission cut proposals from the IRDAI. The brokerage noted that reduced take rates in the general insurance business cannot cover current costs, making the next 18 months 'do-or-die' for the company.
The IRDAI proposed tighter limits on insurers' management expenses alongside commission cuts ranging from one-half to two-thirds across health, motor, and term insurances. These reforms aim to curb distribution costs, expand coverage to underserved populations, and bring greater discipline to the industry.
Other brokerages also adjusted their outlooks following the draft guidelines, with HSBC downgrading its rating and cutting its target price to ₹1,150. Investec lowered its target price by 43% to ₹1,425, while overall market coverage shows 15 buy ratings, six hold ratings, and four sell ratings.
